Find a Tender · Contract
NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL
A public procurement published by Belfast Health and Social Care Trust (BHSCT) via Find a Tender.
- £680k
- Award value
- —
- Tender value
- 1
- Suppliers
- 1
- Awards
- 2
- Notices
- Contract
- Stage
Overview
Procurement of NORMAL IMMUNOGLOBULIN HUMAN (XEMBIFY) SOLUTION FOR INJECTION VIAL
Key details
- Source
- Find a Tender
- Lifecycle stage
- Contract
- Status
- complete
- CPV classification
- —
- Currency
- GBP
- Total award value
- £680,000
- Tender value
- —
- First published
- 7 May 2026
- Last updated
- 7 May 2026
Awards
1 award recorded on this procurement.
| Supplier | Companies House | Awarded | Status | Value |
|---|---|---|---|---|
| Healthnet Homecare UK Ltd. | 06856641 | 6 May 2026 | pending | £680k |
Notice timeline
Every published notice in this procurement's lifecycle.
All suppliers
Frameworks & programmes
More from Belfast Health and Social Care Trust (BHSCT)
FAQs about this procurement
Who is the buyer for "NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL"?
NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL is a UK public-sector procurement published by Belfast Health and Social Care Trust (BHSCT) via Find a Tender.
Has "NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL" been awarded?
Yes — 1 award is recorded, with a reported total value of £680,000. The current lifecycle stage is "Contract".
Which suppliers are involved in "NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL"?
1 supplier is linked: Healthnet Homecare UK Ltd..
What is "NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL" worth?
The reported award value is £680,000.
When was "NORMAL IMMUNOGLOBULIN HUMAN XEMBIFY SOLUTION FOR INJECTION VIAL" published?
It was first published on 7 May 2026 and last updated on 7 May 2026, across 2 notices.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable